Oxford Biomedica rejects GeneThera approach
This article was originally published in Scrip
Executive Summary
GeneThera's goal of moving into the human DNA vaccine sector remains unfulfilled after Oxford BioMedicadismissed its takeover approach. The UK biotech company rejected an unsolicited bid from the US animal health and agricultural firm after concluding that GeneThera was "not a credible bidder".